Author: diondkagan

YouTube video landing page with pictures of the three presenters, Dion Kagan, Emily Lenton and Sean Mulcahy, with text reading 'ARCSHS Summer Research Schowcase - Watch on Youtube'

Watch the GLaD team’s summer research showcase

diondkagan

Recently, GLaD reserchers Sean Mulcahy, Emily Lenton and Dion Kagan presented a 3-part showcase of research findings from current projects addressing LGBTIQA+ human rights, hepatitis C data justice, and life after hepatitis C cure. Watch a recording of their papers here.

Community Presentation

Inaugural Australian stigma conference hears call to address the health and human rights of people who use drugs

diondkagan

GLaD research lead Kate Seear gave a keynote presentation at the inaugural Australian Stigma Conference hosted by the Australian Injecting & Illicit Drug Users League (AIVL) in Canberra calling for reform to legal, social, policy and cultural dimensions of hepatitis C in order to better to address the health and human rights of people who use drugs.

Illustration of a crowd of many diverse people with their hands tied or handcuffed behind their backs

Presentation Project update

Post-cure and post-human rights – recent findings presented at the Australian Sociological Association conference

diondkagan

GLaD program lead Kate Seear and project officer Dion Kagan presented recent findings at The Australian Sociological Association conference earlier this month.

Announcement New article Publications Research

Complicating Cure

diondkagan

The law has the power to shape public understandings of hepatitis C infection, including how people with the virus understand themselves and their ability to avoid the stigma associated with it. The latest article from our project on the experiences of people treated for hepatitis C engages with the challenges posed by laws and policies devised in a pre-cure world.

Announcement Podcast Research

Listen to a showcase of important new research this World Hepatitis Day

diondkagan

To mark World Hepatitis Day in 2022, researchers in the GLaD and DruGS programs at ARCSHS got together with CEO of Hepatitis Australia Carrie Fowlie to share and discuss findings from three recent social research projects on hepatitis C. Listen to the conversation here.

Research

#HepCantWait, but the legacy effect of stigma and discrimination ‘doesn’t just go away’

diondkagan

Since late 2019, COVID-19 has been the global health crisis absorbing much of our attention. Efforts to respond to it, including the redeployment of people and resources, have necessarily had impacts on other public health programs and pandemics. The World Health Organization’s ambitious goal to eliminate hepatitis C by 2030 is one program that has been slowed and, in some places, stopped in its tracks by COVID-19.

Announcement

Post-cure lives – now recruiting

diondkagan

Seeking participants for research on people’s lived experience of hepatitis C cure

Part 2 Project update

Life after cure – preliminary findings from the post-cure project

diondkagan

What does life look like for people after they have cleared hepatitis C?

Part 1 Project update

Life after cure – preliminary findings from the post-cure project

diondkagan

What does life look like for people after they have cleared hepatitis C? Do people whose blood shows no detectable amount of the hepatitis C virus need to inform their doctor or dentist about their previous hepatitis C status? What about prospective employers or insurance providers? Does hepatitis C–related stigma and discrimination remain a challenge for people post-cure? In what ways, and in what settings?

Project update

Hepatitis C cure and ongoing challenges in post-cure lives

diondkagan

Australia is spending billions on the universal rollout of direct-acting antiviral drugs (DAAs) as part of its ambitious goal of achieving virtual elimination of hepatitis C by 2030. These ‘revolutionary’, ‘transformative’ drugs can bring about a sustained virological response – that is, a cure – for hepatitis C in over 90 percent of people treated. They are available on the Pharmaceutical Benefits Scheme for all Australians who are covered by Medicare.

New project

Social research project on hepatitis C and post-cure lives

diondkagan

In Australia, a new generation of direct-acting antivirals (DAAs) for the treatment of hepatitis C have been rolled out in a globally unique program of unrestricted, nationwide access. The new drugs, heralded as ‘revolutionary’, bring about a sustained virological response to hepatitis C in over 90 percent of people treated. By the end of 2019, […]

New article

Beyond a post-cure world

diondkagan

We are excited to announce the publication of the first article from the project, ‘Addressing hepatitis C-related legal, policy and practice discrimination in a post-cure world’.